Last Updated : June 8, 2023
Details
Generic Name:
deucravacitinib
Project Status:
Active
Therapeutic Area:
Psoriasis, moderate to severe plaque
Manufacturer:
Bristol-Myers Squibb Company
Brand Name:
Sotyktu
Project Line:
Reimbursement Review
Project Number:
SR0756-000
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
The treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
The treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | August 29, 2022 |
|---|---|
| Call for patient/clinician input closed | October 24, 2022 |
| Clarification: - Patient input submission received from the Canadian Psoriasis Network (CPN) and Canadian Association of Psoriasis Patients (CAPP) | |
| Submission received | September 27, 2022 |
| Submission accepted | October 12, 2022 |
| Review initiated | October 13, 2022 |
| Draft CADTH review report(s) provided to sponsor for comment | January 03, 2023 |
| Deadline for sponsors comments | January 12, 2023 |
| CADTH review report(s) and responses to comments provided to sponsor | February 09, 2023 |
| Expert committee meeting (initial) | February 22, 2023 |
| Draft recommendation issued to sponsor | March 07, 2023 |
| Draft recommendation posted for stakeholder feedback | March 16, 2023 |
| End of feedback period | March 31, 2023 |
| Clarification: - Reconsideration: major revisions requested by sponsor - Target CDEC reconsideration meeting date to be determined | |
Last Updated : June 8, 2023